What Treatments Can Patients with HER2-positive Breast Cancer Have?
' + "
";
evCat = 'adx-impl';
evLabel = '/21865806531/yl-xk/336*280-01-wap-xk-yl';
} else {
html = "
" + '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/728*90-01-pc-xk-yl", [728, 90], "div-gpt-ad-1576640512222-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640512222-0")});
' + "
";
evCat = 'adx-impl';
evLabel = '/21865806531/yl-xk/728*90-01-pc-xk-yl';
}
var html2 = replaceAll2(html, "script2", "script");
fillHtml += randomAdxSlotId(html2);
_pf_event(evCat, PAGE_CAT, evLabel);
_pf_log("ga adsense single");
}
document.write(fillHtml);
}
showAd();
})();
Q:
What treatments can patients with HER2-positive breast cancer have?
A:
There are some treatments particular for HER2-positive breast cancers.
- Herceptin (trastuzumab). It stops the cancer cells from receiving chemical signals so that the cells wonât grow.
- Kadcyla (T-DM1 or ado-trastuzumab emtansine). It combines Herceptin and emtansine. Emtansine is carried by Herceptin to work against HER2-positive cancer cells.
- Nerlynx (neratinib). It also works to stop cancer cells from receiving growth signals.
- Perjeta (pertuzumab). It works against HER2-positive breast cancers by blocking the growth signals that are supposed to be received by the cancer cells.
- Tykerb (lapatinib). It targets certain proteins to stop them from leading to uncontrolled cell growth.
Keywords: her2 breast cancer treatment; her2 breast cancer treatments; her2 positive breast cancer treatment; treatment her2 positive breast cancer
Related FAQs:
What Is HER2-positive Breast Cancer?
What Is HER2 Breast Cancer?
What Is HER1 Breast Cancer?
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
";
}
function showAd(){
var s = getQueryStringByName('s');
var isSearchPage = (s != '');
var isMobile = /iPhone|iPad|iPod|Android/i.test(navigator.userAgent);
var html = '';
var html2 = '';
if (isSearchPage) {
if (isMobile) {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-01-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640284306-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640284306-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-01-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-02-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640310637-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640310637-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-02-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-03-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640337768-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640337768-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-03-wap-n-xk-yl');
} else {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-pc-n-xk-yl", [300, 600], "div-gpt-ad-1576640117816-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640117816-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-pc-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-02-pc-n-xk-yl", [300, 600], "div-gpt-ad-1576640172416-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640172416-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-02-pc-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl", [300, 600], "div-gpt-ad-1576639775063-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639775063-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl');
}
} else {
if (isMobile) {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-04-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640363074-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640363074-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-04-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-05-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640388002-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640388002-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-05-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-06-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640412938-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640412938-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-06-wap-n-xk-yl');
} else {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl", [300, 600], "div-gpt-ad-1576639775063-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639775063-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x250-01-healthtopquestions-xk-yl", [300, 250], "div-gpt-ad-1576639270555-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639270555-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x250-01-healthtopquestions-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl", [300, 600], "div-gpt-ad-1576639775063-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639775063-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl');
}
}
var html2 = replaceAll2(html, 'script2', 'script');
document.write(html2);
}
showAd();
})();